PI
Dosage & Administration
COMET
Any clinical data
100

In which patients is Nexviazyme contraindicated

Patients with life threatening hypersensitivity to the active substance or any of the excipients when re-challenge was unsuccessful 

100

What is the recommended initiation rate for Nexviazyme infusion?

1 mg/kg/hour

100

What was the primary endpoint of the COMET study?

Change in forced vital capacity in the upright position from baseline to week 49

100

What is the pregnancy category of Nexviazyme?

B1

200

What is the indication for Nexviazyme?

For long-term ERT for the treatment of patients 1 yr or older with Pompe Disease

200

What is the recommended dose of NEXVIAZYME for patients with Infantile onset Pompe disease?

Up to 40 mg/kg administered every other week

200

In what percentage of patients receiving NEXVIAZYME in the COMET Study were serious adverse reactions reported?

2%

200

How many patients receiving NEXVIAZYME in all clinical studies permanently discontinued treatment due to adverse reactions?

Two

300

Is Nexviazyme contraindicated for patients who have acute underlying respiratory illness or compromised cardiac or respiratory function?

No, however monitoring of vital signs more frequently is recommended

300

What is the concentration of the reconstituted solution of NEXVIAZYME prior to dilution?

10 mg/ml

300

Which adverse drug reactions (ADR) were among the most frequently reported  in patients treated with NEXVIAZYME in the COMET study?

Headache and fatigue

300

In what percentage of patients treated with NEXVIAZYME in pooled clinical studies did infusion-associated reactions (IARs) occur?

30%

400

What should be done if severe hypersensitivity or anaphylaxis occur in a patient receiving NEXVIAZYME?

NEXVIAZYME should be discontinued immediately, and appropriate medical treatment should be initiated.

400

What rate of increases can be made to the Nexviazyme infusion after initiation? (Time and Amt and Maximum).

2 mg/kg/hour every 30 mins to max of 7 mg/kg/hour

400

In what percentage of patients treated with alglucosidase alfa in COMET were infusion-associated reactions (IARs) reported?

32.7% or 16 patients

400

In NEXVIAZYME treated patients, anti-drug antibodies to NEXVIAZYME occurred in __% treatment naive adults and __% switch adults.

95.1 and 49.1

500

Should desensitisation procedures be considered for a patient who is having a severe hypersensitivity reaction to Nexviazyme?

YES

500

How many milligrams of Nexviazyme powder are contained in one vial?

100 mg

500

In the COMET study, what was the estimated difference between NEXVIAZYME and alglucosidase alfa in FVC percentage predicted, that achieved statistical non-inferiority? 

2.4%

500

What was the incidence of treatment-emergent anti-drug antibody (ADA)response to NEXVIAZYME in treatment-naïve patients?

95% or 58 patients